Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Gdynia – page 16

232 clinical trials in Gdynia, Poland across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Gdynia at a glance
232
clinical trials
  • Paediatric trials0
  • Research sites2
Type of trial
Recruitment status
Quick filters

232 trials in Gdynia

Open in trial search

Breast cancer metastatic

Not recruiting

Study comparing giredestrant plus palbociclib versus letrozole plus palbociclib in patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Giredestrant
  • Sponsor:F. Hoffmann-La Roche AG

Prostate cancer metastatic

Not recruiting

Study of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Janssen Cilag International

Prostate cancer metastatic

Not recruiting

Study of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Metastatic Prostate Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Janssen Cilag International

Follicle centre lymphoma follicular grade I II - III refractory

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Migraine

Not recruiting

Study on Eptinezumab for Preventing Chronic Migraine in Adults

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Eptinezumab
  • Sponsor:H. Lundbeck A/S

Non-small cell lung cancer

Not recruiting

Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Daiichi Sankyo Inc.

Colitis ulcerative

Not recruiting

Study on the Effects of Oxygen Therapy with Vedolizumab, Ustekinumab, or Infliximab for Adults with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:Medical University Of Gdansk

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing ACP-196 and Ibrutinib for Patients with High-Risk Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Neoplasm malignant+1

Not recruiting

Study of AZD5305 Alone and with Other Cancer Drugs for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant
  • Sponsor:AstraZeneca AB

Mantle cell lymphoma

Not recruiting

Study of Zanubrutinib and Rituximab Compared to Bendamustine and Rituximab for Patients with Untreated Mantle Cell Lymphoma Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:BeOne Medicines AG

B-cell lymphoma+5

Not recruiting

Study on the Effects and Safety of Odronextamab for Adults with Previously Treated B-cell Non-Hodgkin Lymphoma

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Odronextamab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Type IIa hyperlipidaemia

Not recruiting

Study on the Effectiveness of Enlicitide Chloride in Reducing Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Gdynia

What the registry says about research in the country

01 Respiratory Diseases

Clinical trials focusing on respiratory viral infections, particularly evaluating new vaccines for elderly populations. Studies target both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).

  • Vaccine development for RSV
  • Prevention of respiratory infections
  • Immune response studies
02 Autoimmune Conditions

Comprehensive research into treatments for various autoimmune disorders, including psoriatic arthritis and plaque psoriasis. Studies evaluate novel therapeutics like zasocitinib and tildrakizumab.

  • Psoriasis management
  • Inflammatory bowel disease treatments
  • Arthritis therapies
03 Cardiovascular Research

Innovative trials investigating treatments for heart failure prevention and cardiovascular disease. Studies examine combination therapies and novel compounds for improving cardiac outcomes.

  • Heart failure prevention
  • Cardiovascular risk reduction
  • Combination therapy evaluation
04 Oncology Studies

Advanced research in breast cancer and prostate cancer treatments, focusing on metastatic disease and novel therapeutic combinations.

  • Metastatic breast cancer therapy
  • Prostate cancer treatment
  • Combination therapy approaches
Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.